IRIDEX Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
108
- Stock Symbol
-
IRIX
- Investments
-
3
- Share Price
-
$0.69
- (As of Friday Closing)
IRIDEX General Information
Description
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Contact Information
Website
www.iridex.comCorporate Office
- 1212 Terra Bella Avenue
- Mountain View, CA 94043
- United States
Corporate Office
- 1212 Terra Bella Avenue
- Mountain View, CA 94043
- United States
IRIDEX Stock Performance
As of 13-Nov-2026, IRIDEX’s stock price is $0.69. Its current market cap is $12.1M with 17.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.69 | $0.71 | $0.61 - $1.65 | $12.1M | 17.6M | 383K | -$0.20 |
IRIDEX Financials Summary
As of 30-Jun-2026, IRIDEX has a trailing 12-month revenue of $51.6M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 25,611 | 24,809 | 28,997 | 40,571 |
| Revenue | 51,573 | 52,675 | 48,669 | 51,869 |
| EBITDA | (1,873) | (2,833) | (7,418) | (7,448) |
| Net Income | (3,547) | (4,437) | (8,910) | (9,570) |
| Total Assets | 27,258 | 29,151 | 29,135 | 34,436 |
| Total Debt | 4,013 | 4,532 | 4,643 | 2,746 |
IRIDEX Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IRIDEX Comparisons
Industry
Financing
Details
IRIDEX Competitors (16)
One of IRIDEX’s 16 competitors is Alcon, a Corporate Backed or Acquired company based in Geneva, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alcon | Corporate Backed or Acquired | Geneva, Switzerland | ||||
| Nova Eye Medical | Corporation | Kent Town, Australia | ||||
| Medtronic | Corporation | Minneapolis, MN | ||||
| Glaukos | Formerly VC-backed | Aliso Viejo, CA | ||||
| Stryker | Formerly VC-backed | Portage, MI |
IRIDEX Patents
IRIDEX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4812136-A1 | Sector probe system for the delivery of laser energy | Pending | 22-Nov-2023 | ||
| US-20250161115-A1 | Sector probe system for the delivery of laser energy | Pending | 22-Nov-2023 | ||
| WO-2025111548-A1 | Sector probe system for the delivery of laser energy | Inactive | 22-Nov-2023 | ||
| US-12465522-B2 | Methods and probes for intrascleral laser surgery | Active | 07-Dec-2020 | ||
| US-20220175580-A1 | Methods and probes for intrascleral laser surgery | Active | 07-Dec-2020 | A61F9/00736 |
IRIDEX Signals
IRIDEX Investments & Acquisitions (3)
IRIDEX’s most recent deal was a Corporate Asset Purchase with Topcon (Pascal Laser Product Line). The deal was made on 10-Mar-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Topcon (Pascal Laser Product Line) | 10-Mar-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Topcon Medical Laser Systems | 10-Mar-2021 | Merger/Acquisition | Diagnostic Equipment | ||
| RetinaLabs (Ophthalmology Line) | 08-Apr-2010 | Merger/Acquisition | Surgical Devices |
IRIDEX ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.36 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
IRIDEX FAQs
-
When was IRIDEX founded?
IRIDEX was founded in 1989.
-
Where is IRIDEX headquartered?
IRIDEX is headquartered in Mountain View, CA.
-
What is the size of IRIDEX?
IRIDEX has 108 total employees.
-
What industry is IRIDEX in?
IRIDEX’s primary industry is Other Devices and Supplies.
-
Is IRIDEX a private or public company?
IRIDEX is a Public company.
-
What is IRIDEX’s stock symbol?
The ticker symbol for IRIDEX is IRIX.
-
What is the current stock price of IRIDEX?
As of 13-Nov-2026 the stock price of IRIDEX is $0.69.
-
What is the current market cap of IRIDEX?
The current market capitalization of IRIDEX is $12.1M.
-
What is IRIDEX’s current revenue?
The trailing twelve month revenue for IRIDEX is $51.6M.
-
Who are IRIDEX’s competitors?
Alcon, Nova Eye Medical, Medtronic, Glaukos, and Stryker are some of the 16 competitors of IRIDEX.
-
What is IRIDEX’s annual earnings per share (EPS)?
IRIDEX’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process